Areteia Therapeutics introduces dexpramipexole, a novel oral drug in Phase 3 trials for asthma and COPD, aiming for approval ...
Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...
Using genetics to identify individuals with undiagnosed chronic obstructive pulmonary disease (COPD)
In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples, that can be obtained from a cheek swab or blood test, they can improve identification of people ...
Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...
Researchers reported that a lung MRI technique that uses inhaled gas can identify early patchy lung defects in patients with ...
Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...
A new study highlights the multiple obstacles patients face before receiving a chronic obstructive pulmonary disease ...
Upgrades aim to improve asthma relief and COPD treatment with advanced technology.United States, January 31, 2025 -- TruNeb ...
Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...
During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...
A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback